+390677209020 | +39 0267380552 info@direnzo.biz | sedemilano@direnzo.biz | Italian Language

New GMP for veterinary medicinal products

GMP Veterinary

The European Commission recently published the implementing regulations for the good manufacturing practice (GMP) for veterinary medicinal products and active substances used as starting materials. This is a relevant regulating step, introducing a dedicated legal framework, directly applicable in all Member States.

The entering into force of the new requirements has been fixed in July 2026, but the time available to comply should not be underestimated. For many companies, in fact, this is going to be more than just a formal change, it will require a careful review of quality systems, manufacturing processes, and GMP documentation.

What changes with the new veterinary GMP regulations

So far, the GMP for veterinary medicinal products were mainly regulated by the EudraLex Volume 4 guidelines, largely aligned to those for the human medicinal products. With the new Regulations:

  • the GMP for veterinary products becomes legally binding rules, not just simple guidelines;
  • an independent regulating system is introduced, specifically thought for the peculiarities of the veterinary sector;
  • a general alignment with the human medicinal product GMP is maintained, but with adjustments and clarifications requiring careful and competent interpretation.

This increases regulatory certainty, raising at the same time the level of responsibility for manufacturers and all operators involved in the production chain.

Key difficulties for companies

Operationally, companies could face several criticalities in their pathway to compliance:

Interpretation of the new requirements

Although many GMP principles are well known, the switch from the guidelines to the regulations implies new inspection expectations. Understanding what has really changed, and what needs only a formal adjustment, is not always easy.

Gaps between the existing system and the new obligations

Many quality systems were built over the years on “hybrid” human/veterinary requirements. The new Regulations impose to reconsider procedures, responsibilities and documental flows, identifying any gaps before they arise during inspections.

GMP documentation update

Site Master Files, SOPs, Quality Manuals, agreements with suppliers and contractors shall be consistent with the new legal framework. This requires time, method and overview.

Preparations for inspections

Competent Authorities will apply the new Regulations as primary reference. Companies that are not adequately prepared risk critical objections, with a direct impact on manufacturing continuity and relevant authorisations.

Our support to companies

In this evolving scenario, Di Renzo Regulatory Affairs supports veterinary companies with solid regulatory assistance, that is customised and compliance-oriented.

GMP impact analysis and gap assessment

We systematically evaluate the gap between the existing GMP system and the new regulations, identifying priority areas and reducing any risk of unwelcome surprises during inspections.

Support for the quality system compliance

We support companies in the review and update of the GMP documentation, ensuring regulatory consistency and operative applicability, with no further burden in the process.

Practical and inspection-oriented approach

Our support takes into account any expectations of the Competent Authorities, helping companies to be effectively ready for any future GMP inspection under the new regulatory framework.

Targeted training

We offer dedicated training for the Quality Assurance, Manufacturing and Regulatory Affairs departments, focusing on the changes introduced by the new veterinary GMP regulations, and their practical impact.

Getting ready today to prevent any critical issue tomorrow

The compliance with the new GMP regulations for veterinary medicinal products should not be seen as a mere regulatory obligation, but as a new opportunity to strengthen quality systems and corporate regulatory solidity.

Starting in time, with the support of an expert partner, enables to face the transition systematically, reducing risks, costs and any operative impacts.

Di Renzo Regulatory Affairs is at your side to turn the complexities of the regulations into a clear, sustainable and fully compliant pathway.